Current opinion in investigational drugs (London, England : 2000) · 2001
A clinical focus on statins.
Сравнительное исследованиеСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Auer J, Eber B
Аннотация
Clinical trials have demonstrated that inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins) significantly reduce cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. Furthermore, statins are currently the most potent cholesterol-lowering drugs available. Subanalyses of the LIPID study have shown that patients suffering from unstable angina pectoris had at least the same benefit from statin therapy as did patients after myocardial infarction. Studies, recently published (AVERT or MIRACL) provide more information on the topic of therapy with statins in the early phase of acute coronary syndromes.
Предметные рубрики MeSH
Angina PectorisAngioplasty, Balloon, CoronaryAnticholesteremic AgentsAtorvastatinCholesterolCholesterol, LDLClinical Trials as TopicCoronary DiseaseCost-Benefit AnalysisDown-RegulationFatty Acids, MonounsaturatedFluvastatinHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIndolesLovastatinMulticenter Studies as TopicMyocardial InfarctionPractice Guidelines as TopicPravastatinPyrrolesQuality of LifeRandomized Controlled Trials as TopicSimvastatin